[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Lee's Pharmaceutical Limited\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":134},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,41,64,88,111],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100589364","phase-1-a-study-of-inhaled-fentanyl-aerosol-in-chinese-patients-with-malignant-tumors-100589364",false,"NCT06953453","A Study of Inhaled Fentanyl Aerosol in Chinese Patients With Malignant Tumors","A Phase I Clinical Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Inhaled Fentanyl Aerosol (25µg\u002FDose) in Chinese Patients With Malignant Tumors","Inclusion Criteria:\n\n1. Volunteer to participate, understand and sign the informed consent form before conducting the evaluation project;\n2. Male or female subjects, aged between 18 and 55, including 18 and 55 years old;\n3. Patients with malignant tumors diagnosed by histology or cytology;\n4. Body Mass Index (BMI) is \\>21 kg\u002Fm2, but \\\u003C30 kg\u002Fm2;\n5. Have sufficient hematopoietic function and organ function within the last 14 days at random.\n\n   1. The absolute neutrophil count is ≥1.5×109\u002FL (has not received colony stimulating factor treatment within 14 days before the examination);\n   2. Platelet count ≥80×109\u002FL (without transfusion of platelets or other platelet-increasing drugs within 14 days before the examination);\n   3. Hemoglobin ≥90g\u002FL (without transfusion or treatment with other hemoglobin-increasing drugs within 7 days before the examination);\n   4. Creatinine clearance rate (Ccr)≥30 ml\u002Fmin, Cr≤2 times the upper limit of normal value;\n   5. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) should be ≤2.5×ULN, and for subjects with liver metastasis, it should be ≤5×ULN; total bilirubin should be ≤2 times the upper limit of normal value;\n   6. Coagulation function INR≤1.5 ULN;\n   7. In a non-oxygen-absorbing state, the oxygen saturation (from a pulse oximeter) is SaO2\\>95%; pulmonary function shows FEV1\u002FFVC\\>70% and FEV1 as a percentage of the predicted value is\\>80%;\n6. All patients must agree to take effective contraceptive measures during the study and within one month after stopping treatment. Female patients of childbearing age must have a negative blood pregnancy test before administration;\n7. The ECOG performance status score is 0\\~1 points;\n\nExclusion Criteria:\n\n1. known or suspected allergy to opioids;\n2. used opioids within 14 days before the first administration, including but not limited to: codeine, dihydrocodeine, hydromorphone, oxycodone, methadone, morphine, fentanyl and pethidine (pethidine);\n3. plan to receive radiotherapy and \u002F or systemic chemotherapy within 14 days before the first administration or during the study period (except for patients who receive immune checkpoint inhibitors or targeted drug maintenance therapy that is not a CYP3A4 inhibitor \u002F inducer and whose condition is stable);\n4. within 14 days before the first administration, the patient had received any monoamine oxidase (MAO) inhibitors (such as phenelzine, isocarbazine, chlorogiline, toloxadone, moclobemide, selegiline, rasagiline, etc.); Or have used CYP3A4 inhibitors (such as indinavir, nelfinavir, ritonavir, clarithromycin, itraconazole, nefazodone, ketoconazole, telithromycin, arepitan, erythromycin, fluconazole, grapefruit, verapamil, diltiazem, cimetidine, etc.) or CYP3A4 inducers (such as phenobarbital, carbamazepine, efavirenz, glucocorticoids, modafinil, nevirapine, oxcarbazepine, phenytoin, pioglitazone, rifabutin, rifampicin);\n5. have participated in other clinical studies or received surgical treatment within 30 days before the screening period, or have surgery plans during the study period;\n6. subjects who smoked more than 10 cigarettes \u002F day within 3 months before the screening period;\n7. subjects with a history of drug or alcohol dependence or abuse within 2 years before the screening period;\n8. subjects often eat food rich in xanthine (such as drinking more than 5 cups of coffee or food containing the same amount of xanthine every day);\n9. subjects with hypotension (systolic blood pressure \\\u003C90 mmHg, or diastolic blood pressure \\\u003C60 mmHg) or uncontrollable hypertension (refers to systolic blood pressure ≥ 160 mmHg, and \u002F or diastolic blood pressure ≥ 100 mmHg after standard treatment);\n10. After antiviral treatment, HBV DNA\\>500 IU\u002FmL or\\>2500 copies\u002FmL; HCV-RNA positive; Positive for human immunodeficiency virus antibodies; Or positive for syphilis antibodies;\n11. subjects with positive alcohol test or urine test at any visit of the study;\n12. subjects with an expected survival time of \\\u003C1 year;\n13. subjects with clinically significant ECG abnormalities during screening;\n14. subjects with a history of lung diseases (asthma, bronchitis, bronchospasm, emphysema, interstitial lung disease, pulmonary fibrosis, etc., excluding lung malignancies);\n15. subjects with history of unstable angina pectoris, syncope, coronary artery disease, myocardial infarction, congestive heart failure (CHF), stroke, transient ischemic attack (TIA) or major neurological diseases;\n16. presence of meningeal metastasis or CNS metastasis requiring clinical intervention or malignancy related epilepsy;\n17. women of childbearing age or lactating women with positive blood and urine pregnancy tests;\n18. the investigator believes that any other situation that may affect the subject's provision of informed consent or compliance with the trial protocol, or the subject's participation in the trial may affect the trial results or their own safety.","ALL","18 Years","55 Years",{"count":20,"type":21},100,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","This study is a single-dose, open-label, 2-cycle crossover design, comparing the pharmacokinetic parameters and safety of Inhaled Fentanyl Aerosol and intravenous fentanyl injection.",[27],"Cancer","RECRUITING","2025-09-24",{"date":31,"type":32},"2025-09-25","ACTUAL",{"date":34,"type":32},"2025-09-23",{"date":36,"type":21},"2026-08-20",{"name":38,"class":39},"Lee's Pharmaceutical Limited","INDUSTRY",2,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":22,"phases":51,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":63},"100544868","phase-1-study-of-au409-capsule-in-advanced-hepatocellular-carcinoma-patients-who-failed-standard-treatment-100544868","NCT06374485","Study of AU409 Capsule in Advanced Hepatocellular Carcinoma Patients Who Failed Standard Treatment","A Phase I, Single-arm, Open-label, Dose-escalation, Safety and Pharmacokinetic Study of AU409 Capsule in Advanced Hepatocellular Carcinoma Patients Who Failed Standard Treatment","Inclusion Criteria:\n\n1. Male or female of 18-75 (inclusive) years of age.\n2. Patients with histologically and\u002For cytologically and\u002For radiologically confirmed advanced (unresectable or metastatic) hepatocellular carcinoma (HCC) that have failed any of standard treatment (including Immunotherapies and\u002For Tyrosine Kinase Inhibitor therapies, or Oxaliplatin-based systemic chemotherapies), recurrence, or are intolerant.\n3. Before treatment initiation, patients must have previously completed chemotherapy, radiotherapy, interventional therapy for more than 4 weeks (except palliative radiotherapy for bone metastasis). And all treatment-related toxicities (except hair loss, pigmentation, and chemotherapy-related neurotoxicities, etc.) have recovered (≤ level 1 or baseline level).\n4. Have at least one evaluable disease lesion based on the modified Response Evaluation Criteria in Solid Tumors (mRECIST).\n5. ECOG score of 0 or 1.\n6. Patients with Child Pugh class A or some class B (≤7 and no hepatic encephalopathy).\n7. Have a life expectancy of \\>12 weeks.\n8. Able to be orally administered.\n9. Laboratory examinations must meet the following criteria within 7 days before treatment initiation:\n\n   * Absolute neutrophil count（ANC）≥1.5 × 109\u002FL，platelets（PLT） count ≥75 × 109\u002FL，hemoglobin（HGB）≥90 g\u002FL，and patients are not allowed to receive blood transfusion or other haematopoietic growth factors within 14 days before treatment initiation.\n   * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) should be ≤5.0×upper limit of normal (ULN).\n   * Total bilirubin (TBIL) ≤1.5×ULN.\n   * Ablumin (ALB) ≥28g\u002FL.\n   * Serum creatinine (CRE) ≤1.0×ULN, creatinine clearance rate (CCR) ≥60 mL\u002Fmin (Cockcroft-Gault equation).\n   * International normalized ratio（INR）≤1.5，prothrombin time (PT) ≤1.5×ULN.\n10. Have a negative serum pregnancy test for premenopausal women (postmenopausal women who have been menopausal for at least 12 months are considered as infertile). For male patients (including male patients' female spouses of child-bearing potential) and female patients of child-bearing potential must be contraceptive throughout the study and within the 6 months following the last dose of AU409.\n11. Patients voluntarily give written informed consent form (ICF).\n\nExclusion Criteria:\n\n1. Patients of central nervous system metastasis with clinical symptoms (except patients who are asymptomatic, and no disease progression confirmed by MRI diagnosis for more than 28 days).\n2. Allergies to any ingredients or excipients in AU409.\n3. Treatment with other anticancer therapies (including surgery, radiation therapy, chemotherapy, anti-angiogenic therapy, targeted therapy, or radiofrequency ablation therapy, etc.) or investigational therapy (except patients who stop treatment of Chinese patent medicine or Chinese herbal medicine for more than 7 days, or complete palliative radiotherapy for bone metastasis \\>2 weeks) within 28 days prior to the first dosing.\n4. QTc ≥470 msec during screening period (Fridericia's equation) or with a history of congenital long QT syndrome.\n5. Patients with history of gastrointestinal surgery that may change the absorption and activity of drugs in their body (such as total gastrectomy, small bowel resection, external bile shunt, etc.) in combination with refractory hiccups, nausea, vomiting, and other diseases that affect drug absorption (such as peptic ulcer, inflammatory bowel disease, lactose intolerance, malabsorption syndrome or chronic diarrhea, etc.).\n6. Patients who require serous effusion for continuous drainage or drug infusion (such as ascites, pleural effusion, etc.), or have undergone portal vein shunt.\n7. Patients with gastrointestinal perforation and\u002For fistula, abdominal abscess, visceral fistula, intestinal obstruction, hepatic encephalopathy, portal vein and inferior vena cava cancer thrombus within 3 months prior to the treatment initiation.\n8. Patients have gastrointestinal bleeding (including esophageal or gastric varices, local active ulcer lesions, etc.), or have a clear bleeding tendency, or are receiving anticoagulation\u002Fthrombolytic therapy within 3 months before treatment initiation. Positive result of occult blood needs to identifythe causes.\n9. Patients with interstitial lung disease, non-infectious pneumonia.\n10. History of allogeneic stem cell transplantation or organ transplantation.\n11. Patients who receive major surgery (except biopsy and puncture) or with major trauma within 28 days before treatment initiation.\n12. Patients with infectious diseases that affect daily activities or require systemic treatment (such as the use of hormones, antibiotics, antifungal drugs, antiviral drugs, and oxygen inhalation), including but not limited to infections requiring hospitalization, bacteremia, severe pneumonia, etc.\n13. Uncontrolled diseases, including a) New York Heart Association (NYHA) Class II or higher heart failure, b) Severe\u002Funstable angina pectoris, c) Primary cardiomyopathy, d) Myocardial infarction or coronary\u002Fperipheral artery bypass surgery occurred within 6 months before treatment initiation, e) Uncontrollable high blood pressure, f) Severe arrhythmia requiring medication or intervention, g) Echocardiographic left ventricular ejection fraction \\\u003C50% during the screening period, h) Deep vein thrombosis\u002Farterial thrombosis \u002FPulmonary vein embolism occurred within 2 months before treatment initiation, i) Cerebrovascular accident or transient ischemic attack occurred within 6 months before treatment initiation, j) Ocular lens disease (such as cataract), k) Diabetes that has not been effectively controlled, l) Thyroid diseases that have not been effectively controlled, m) Urine protein≥2+ and quantity of 24-hour urine protein ≥1.0g.\n14. Human immunodeficiency virus infection (HIV 1\u002F2 antibody positive).\n15. HBV infection (HBsAg positive and HBV DNA ≥2000 IU\u002FmL); Hepatitis C virus (HCV) antibody is positive and HCV RNA\\>103 copies\u002Fml; HBsAg and HCV antibodies are both positive.\n16. Patients with tuberculosis (TB) who need to receive\u002Fare receiving anti-TB treatment within 1 year before treatment initiation.\n17. Pregnant or nursing；\n18. Patients complicated with other malignant tumors within 5 years before treatment initiation, except various in situ tumors, skin basal cell carcinoma or squamous cell carcinoma that have been cured in the past, local prostate cancer receiving radical operation, and in situ breast ductal carcinoma receiving radical operation.\n19. Patients with other severe, acute, chronic, or psychiatric illnesses that may increase the risk of treatment or may interfere with interpretation of the trial results. And patients with alcoholism, smoking addiction, drug abuse, and other circumstances that are not conductive to the treatment or explain adverse events, thereby contributing to decrease study compliance.\n20. Other conditions that are not suitable for participating in the study in the opinion of investigator.\n21. Patients who were treated with pentamidine prior to treatment initiation or during the study.","75 Years",{"count":50,"type":21},18,[24],"This study is a Phase I, dose-escalation study of AU409 in advanced hepatocellular carcinoma patients who failed standard treatment. A '3+3' dose-escalation design will be utilized to gradually increase the dose of AU409, aiming to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor efficacy of multi-dose AU409 in patients with advanced HCC.",[54],"Advanced Hepatocellular Carcinoma","2025-08-19",{"date":57,"type":32},"2025-08-26",{"date":59,"type":32},"2024-05-21",{"date":61,"type":21},"2025-12-31",{"name":38,"class":39},1,{"id":65,"slug":66,"hasResults":11,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":70,"eligibilityCriteria":71,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":72,"enrollmentInfo":73,"targetDuration":4,"studyType":75,"phases":4,"briefSummary":76,"conditions":77,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":63},"100600565","inhaled-nitric-oxide-for-the-treatment-of-neonatal-hypoxic-respiratory-failure-with-pulmonary-hypertension-100600565","NCT07099144","Inhaled Nitric Oxide for the Treatment of Neonatal Hypoxic Respiratory Failure With Pulmonary Hypertension","A Prospective, Open, Single-arm, Multi-center Phase IV Clinical Study of Inhaled Nitric Oxide Combined With Ventilatory Support for the Treatment of Neonatal (Gestational Age ≥34 Weeks) Hypoxic Respiratory Failure With Pulmonary Hypertension.","INOFTTONHRFWPH","Inclusion Criteria:\n\n1. Neonates ≥ 34 weeks gestation age.\n2. Hypoxic respiratory failure requiring more than 24 hours of ventilatory support.\n3. Clinical or echocardiographic evidence of pulmonary hypertension (systolic pulmonary arterial pressure \\[sPAP\\] \\> 35 mm Hg or \\> 2\u002F3 systemic blood pressure \\[SBP\\] or there is a right-to-left shunt at the atrium or arterial ductus).\n4. Age less than 7 days at the time of treatment initiation with study drug.\n5. The neonatal guardian agrees to participate in the study and signs an informed consent form (ICF).\n\nExclusion Criteria:\n\n1. Neonates dependent on right-to-left shunting of blood.\n2. Neonates whose mother has been treated with anticoagulant therapies during pregnancy.\n3. Echocardiography confirmed left-to-right shunt or left ventricular dysfunction.\n4. ECMO is urgently needed, or neonate has received ECMO.\n5. Patient is at risk of imminent death (death expected within 24 hours).\n6. Life-threatening abnormality (cranial, cardiac, thoracic).\n7. Chromosomal abnormality.\n8. Congenital diaphragmatic hernia\n9. Congenital heart defect (other than patent ductus arteriosus or small atrial septal defect).\n10. Neonate has been resuscitated requiring chest compressions within 6 hours of study treatment start.\n11. Significant bleeding diathesis such as grade IV intraventricular hemorrhage or periventricular leukomalacia, pulmonary hemorrhage, uncontrolled bleeding or hemodynamic failure.\n12. Disseminated intravascular coagulopathy.\n13. Active seizures while receiving anticonvulsants.\n14. Experienced prolong asphyxia with evidence of severe acidosis (pH\\\u003C7.25)\n15. Receiving nitric oxide donor agents such as prilocaine, sodium nitroprusside, nitroglycerin, and sulfonamides.\n16. Other subjects determined by the investigator to be unsuitable for inclusion.","7 Days",{"count":74,"type":21},120,"OBSERVATIONAL","This is a prospective, open-label, single-arm, multicenter Phase IV clinical study to evaluate the safety of INOmax for the treatment of hypoxic respiratory failure with pulmonary hypertension in newborns (≥ 34 weeks gestational age). To evaluate the safety of INOmax combined with ventilatory support in the treatment of neonatal (≥ 34 weeks gestational age) hypoxic respiratory failure with pulmonary hypertension.",[78,79],"Pulmonary Hypertension","Hypoxic Respiratory Failure","2025-07-29",{"date":82,"type":32},"2025-08-01",{"date":84,"type":32},"2024-12-12",{"date":86,"type":21},"2026-12-30",{"name":38,"class":39},{"id":89,"slug":90,"hasResults":11,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":4,"eligibilityCriteria":94,"healthyVolunteers":11,"sex":95,"minAge":17,"maxAge":48,"enrollmentInfo":96,"targetDuration":4,"studyType":22,"phases":98,"briefSummary":100,"conditions":101,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":5},"100551407","phase-3-phase-iii-study-of-socazolimab-as-first-line-treatment-in-persistent-recurrent-or-metastatic-cervical-cancer-100551407","NCT06459687","Phase III Study of Socazolimab as First-Line Treatment in Persistent, Recurrent, or Metastatic Cervical Cancer","Efficacy and Safety of Socazolimab Combined With Chemotherapy With or Without Bevacizumab as First-Line Treatment in Persistent, Recurrent, or Metastatic Cervical Cancer: A Randomized, Double-blind, Placebo-controlled Phase III Study","Inclusion Criteria:\n\n* 1\\. Able to understand and voluntarily signed written informed consent. Informed consent must be signed prior to specified study procedure.\n* 2\\. Age ≥ 18 years and ≤75 years on the date of signing the informed consent, female.\n* 3\\. ECOG Physical fitness score was 0 or 1.\n* 4\\. Life expectancy ≥ 3 months.\n* 5\\. Histologically confirmed cervical cancer that cannot be cured by surgery or radiotherapy\u002Fconcurrent chemoradiotherapy.\n* 6\\. Have at least one measurable tumor lesion examined by CT or MRI according to RECIST v1.1 criteria;\n* 7\\. All subjects must provide archived or freshly obtained tumor tissue samples (formalin-fixed paraffin-embedded \\[FFPE\\] tissue wax blocks or at least 5 unstained tumor tissue section samples, preferably newly obtained tumor tissue samples) within the previous 5 years of randomization.\n* 8\\. Laboratory examination results during the screening period indicate that the subject has good organ function.\n* 9\\. Effective contraception should be used by fertile female subjects from the signing of informed consent until 180 days after the last administration of the study drug.\n\nExclusion Criteria:\n\n* 1\\. Other histopathological types of cervical cancer, such as small cell carcinoma, clear cell carcinoma, sarcoma, etc.\n* 2\\. Prior anti-angiogenic therapy (e.g., bevacizumab), immune checkpoint inhibitors (e.g., anti-PD-1 antibody, anti-PD-L1 antibody, anti-CTLA-4 antibody, etc.), or targeting immune costimulators (e.g. antibodies against ICOS, CD40, CD137, GITR, OX40 targets, etc.) and any treatment targeting the immune mechanism of tumor.\n* 3\\. Active or potentially recurring autoimmune disease.\n* 4\\. Patients with other active malignant tumors within 3 years prior to randomization.\n* 5\\. Participants who had participated in other clinical studies and used other clinical trial drugs within 4 weeks before randomization.\n* 6\\. Major surgery, open biopsy or significant trauma within 4 weeks before randomization; Or an expected major surgical treatment during the study.\n* 7\\. Anti-tumor therapy within 4 weeks before randomization.\n* 8\\. Severe infection occurring within 4 weeks prior to randomization.\n* 9\\. Vaccination within 4 weeks prior to randomization.\n* 10\\. Received immune-modulating drugs (such as thymosin, interferon, interleukin-2) within 2 weeks before randomization.\n* 11\\. Use of systemic antibacterial, antiviral, or antifungal drugs within 2 weeks prior to randomization.\n* 12\\. Subjects requiring systemic treatment with corticosteroids (\\> 10 mg\u002F day of prednisone or equivalent doses of corticosteroids) or other immunosuppressive drugs within 2 weeks prior to randomization.\n* 13\\. Clinically significant hydronephrosis that cannot be relieved by nephrostomy or ureteral stenting as determined by the investigator.\n* 14\\. Central nervous system metastatic or cancerous meningitis.\n* 15\\. Uncontrolled pleural, pericardial, or peritoneal effusions requiring repeated drainage (more frequently than monthly).\n* 16\\. Known primary or secondary immunodeficiency, including a positive test for human immunodeficiency virus (HIV) antibodies.\n* 17\\. Known history of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation.\n* 18\\. Known active tuberculosis; Known active treponema pallidum infection.\n* 19\\. known history of severe hypersensitivity to other monoclonal antibodies.\n* 20\\. Known contraindications to cisplatin\u002Fcarboplatin, paclitaxel, or allergies to any components.\n* 21\\. Previous and\u002For current presence of interstitial lung disease, pneumoconiosis, drug-related pneumonia, severe impairment of pulmonary function, etc., that may interfere with the detection and management of suspected drug-related pulmonary toxicity.\n* 22\\. Subjects with active viral hepatitis B, inactive or asymptomatic carriers of hepatitis B virus (HBV) (positive for hepatitis B surface antigen \\[HBsAg\\]) with HBV DNA \\> 500 IU\u002FmL or \\> 2500 copies\u002FmL), and subjects with active viral hepatitis C.\n* 23\\. Active or documented inflammatory bowel disease.\n* 24\\. Any of the following cardiovascular diseases: a) myocardial infarction, unstable angina pectoris, pulmonary embolism, aortic dissection, deep vein thrombosis, and any arterial thromboembolism event occurred within 6 months before randomization; b) New York Heart Association (NYHA) heart function grade ≥ II heart failure; c) There is a serious arrhythmia that requires drug intervention; Patients with asymptomatic atrial fibrillation with stable ventricular rate were admitted; d)Left ventricular ejection fraction (LVEF) \\\u003C 50%.\n* 25\\. NCI CTCAE v5.0 ≥ 2 grade peripheral neuropathy.\n* 26\\. Not recovered from toxicity of previous antitumor therapy.\n* 27\\. Pregnant or lactating women.\n* 28\\. Any condition (such as another serious illness or psychiatric disorder) that the investigator believes may result in a risk for acceptance of the study drug or that would interfere with the evaluation of the study drug or with the safety of the subjects or the interpretation of the study results.\n* 29\\. Known contraindications to bevacizumab or allergies to any of its components, or the presence of any medical conditions that could affect the safety of bevacizumab administration.","FEMALE",{"count":97,"type":21},440,[99],"PHASE3","The goal of this clinical trial is to evaluate the efficacy and safety of Socazolimab combined with chemotherapy with or without bevacizumab as first-Line treatment in persistent, recurrent, or metastatic cervical cancer. The main question it aims to answer is:\n\nDoes Socazolimab combined with chemotherapy with or without bevacizumab better benefit patients with persistent, recurrent, or metastatic cervical cancer as first-line treatment compared with placebo combined with chemotherapy with or without bevacizumab.\n\nParticipants will be treated with Socazolimab\u002Fplacebo + chemotherapy ± bevacizumab) for 6\\~8 cycles (Q3w), following maintenance treatment of Socazolimab\u002Fplacebo (Q3w).",[102],"Cervical Cancer","2025-05-11",{"date":105,"type":32},"2025-05-14",{"date":107,"type":32},"2024-11-28",{"date":109,"type":21},"2028-09-01",{"name":38,"class":39},{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":4,"eligibilityCriteria":117,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":118,"enrollmentInfo":119,"targetDuration":4,"studyType":22,"phases":121,"briefSummary":122,"conditions":123,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":40},"100528417","phase-3-phase-iii-clinical-trial-evaluating-the-resection-efficacy-of-5-aminolevulinic-acid-hydrochloride-5-ala-hcl-fluorescence-guided-microsurgery-versus-conventional-white-light-microsurgery-in-patients-with-malignant-glioma-who-grade-34-100528417","NCT06160492","Phase III Clinical Trial Evaluating the Resection Efficacy of 5-Aminolevulinic Acid Hydrochloride (5-ALA HCl) Fluorescence-Guided Microsurgery Versus Conventional White Light Microsurgery in Patients With Malignant Glioma (WHO Grade 3\u002F4)","Phase III Clinical Trial Evaluating the Efficacy of 5-aminolevulinic Acid (5-ALA HCl) Fluorescence-guided Microsurgery Versus Conventional White Light Microsurgical Resection in Patients With Malignant Gliomas (WHO Grade 3\u002F4)","Inclusion Criteria:\n\n* Males or females 18-70 years of age, inclusive;\n* Patients with presumably new malignant gliomas (WHO grade 3\u002F4) diagnosed by imaging;\n* have a Karnofsky Performance Status (KPS) ≥ 60;\n* Ability to take oral medications;\n* Laboratory tests meeting the following criteria within ≤ 7 days preoperatively:\n\nAlanine aminotransferase (ALT), Mentholatum aminotransferase (AST), Glutamyl transpeptidase (GGT) \\\u003C 100 IU\u002FL; Serum total bilirubin (TBIL) \\\u003C 51.3 μmol\u002FL (3.0 mg\u002Fdl); Serum creatinine (CRE) \\\u003C 176.8 μmol\u002FL (2.0 mg\u002Fdl);\n\n* Non-surgically sterilized or female subjects of childbearing potential need to have a negative serum pregnancy test result and must be non-lactating females; female subjects of childbearing potential and male subjects whose spouses are of childbearing potential are voluntarily using contraception for a period of 3 months after administration of the test drug;\n* Subjects are able to understand the informed consent form, voluntarily participate and sign the informed consent form, have good compliance, and cooperate with follow-up visits.\n\nExclusion Criteria:\n\n* Known hypersensitivity to the test drug ingredients, aminoglutaric acid, porphyrins, or their analogs;\n* acute or chronic porphyria; history of cutaneous photosensitivity, actinic dermatoses, and exfoliative dermatitis\n* Tumor located in the midline, basal ganglia, cerebellum, or brainstem;\n* Inability to undergo enhanced MRI (pacemaker, contrast allergy, and other reasons);\n* Subjects taking other trial medications within 30 days prior to the start of this trial or subjects undergoing other clinical trials at the same time;\n* Comorbid uncontrolled cardiac conditions such as: a) New York Heart Association (NYHA) class ≥II, b) severe\u002Funstable angina, c) primary cardiomyopathy, d) myocardial infarction or previous coronary\u002Fperipheral artery bypass grafting within ≤6 months prior to the procedure, e) difficult-to-control hypertension, f) severe arrhythmia requiring medication or intervention, and g) screening echocardiographic left ventricular ejection fraction \\\u003C50%;\n* Active hepatitis B or C (unless HBV-DNA titers below the minimum detection limit and HCV-RNA negative on antiviral therapy can be included), HIV-positive or known history of acquired immunodeficiency syndrome;\n* Any other condition that, in the opinion of the investigator, makes participation in the trial inappropriate;","70 Years",{"count":120,"type":21},144,[99],"This is a randomized, open, parallel-group, multicenter clinical trial evaluating 5-aminolevulinic acid (5-ALA HCl) oral solution with powdered fluorescent microscopic tumor resection versus white light microscopic tumor resection in patients with malignant gliomas (WHO grade 3\u002F4).",[124,125],"5-aminolevulinic Acid","Fluorescence-guided Resection","2025-05-09",{"date":128,"type":32},"2025-05-13",{"date":130,"type":32},"2025-04-14",{"date":132,"type":21},"2026-03",{"name":38,"class":39},""]